Anti-Human CD20 - Purified
Code | Size | Price |
---|
LEI-C1602-50ug | 50 ug | £135.00 |
Quantity:
LEI-C1602-100ug | 100 ug | £165.00 |
Quantity:
LEI-C1602-200ug | 200 ug | £223.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG2b κ
Antibody Clonality: Monoclonal
Antibody Clone: 2H7
Regulatory Status: RUO
Target Species: Human
Applications:
- Flow Cytometry
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunoprecipitation (IP)
Shipping:
2-8°C
Storage:
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
CD20 is present on human pre B lymphocytes and on B lymphocytes, except on plasma cells, and is expressed in tandem with surface IgM. It is also expressed in some follicular dendritic cells and at low levels on a T cell subset.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified
Format:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Purified Recombinant Human CD20 (>98%)
Long Description:
CD20 is a 33-37 kD transmembrane-spanning phosphoprotein that facilitates optimal B-cell immune response against T-independent antigens. It can exist in a complex with MHC class I, MHC class II, CD53, CD81, and CD82. However, CD20 can also form homo-oligomers. It has been suggested that homo-oligomerization of CD20 forms calcium ion channels in the plasma membrane of B cells. CD20 can be useful in diagnosing B-cell lymphomas and leukaemias, and is the target of mAbs in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. Interestingly, studies show a link between the immune system's B cells and diabetes mellitus in which anti-CD20 antibodies rendered the T cell antibodies dysfunctional and, hence, unable to cause insulin desensitivity by a B cell antibody-modulated autoimmune response.
NCBI Gene:
931
Target:
CD20
References
1. Stashenko, P. et al. (1980) J. Immunol. 125:1678
2. Fang, D. et al. (2005) Cancer Res. 65:9328
3. Bubien, J. K. et al. (1993) J. Cell Biol. 121:1121
4. White, M. W. et al. (1991) J. Immunol. 146:846
5. Cragg, M. S. et al. (2005) Curr. Dir. Autoimmun. 8:140
Related Products
Product Name | Product Code | Supplier | Anti-Human CD20 - Purified in vivo PLATINUM™ Functional Grade | LEI-C1651 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anti-Human CD20 - DyLight® 650 | LEI-C1678 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Human CD20 - DyLight® 755 | LEI-C1680 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Human CD20 - PerCP | LEI-C1682 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Human CD20 - PE | LEI-C1895 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Human CD20 - APC | LEI-C1896 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||